Navigation Links
Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Date:5/12/2011

SAN FRANCISCO, May 12, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that key data from its Phase 2 randomized clinical study in advanced liver cancer patients, along with data from other JX-594 clinical trials, will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 18-21, 2011, in Seattle, Washington.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation at the ASGCT Presidential Symposium. Additionally, these data have been chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.

The presentation details are as follows:

Abstract Title: "Demonstration of Safety and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers" (Abstract #50)

Presenter: David H. Kirn, M.D., president and chief executive officer of Jennerex

Session: Presidential Symposium, May 19, 2011, 9:05 a.m. PDT

About JX-594

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
2. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
3. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
4. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
5. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Closes $5 Million First Tranche of Series C Financing
8. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Micell Technologies Reports Preclinical Data for MiStentâ„¢ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
(Date:7/22/2014)... 22, 2014 Automated cell culture systems ... of cell culture. They allow production of optimum cells ... researchers in drug discovery and industries and biopharmaceutical companies. ... production, iPSC research, cryobanking, cell-based assays, and cellular expression ... , Analysts forecast the Global Cell Culture market ...
(Date:7/22/2014)... (NASDAQ: NEOG ) announced today that revenues ... increased 19% from the previous year to $247,405,000. Fiscal ... year,s $27,190,000. Adjusted for a 3-for-2 stock split effective ... year were $0.76, compared to $0.75 a year ago. ... year established new all-time highs for the 32-year-old company. ...
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... ON, April 3 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... months ended February 29, 2008. All dollar amounts referenced ... February 29, 2008, our cash and cash equivalents totaled ... We incurred a net loss for the three ...
... BALTIMORE, April 3, 2008 Alba Therapeutics Corporation,today ... its Chief Executive,Officer (CEO) and a member of ... Partner with SV Life Sciences Advisors, LLC. Previously, ... of the senior management team for several,successful entrepreneurial ...
... LEEDS Standards for Sustainable Development, PLEASANTON, Calif., ... announced the opening of its new research facility,at ... represents the final phase of consolidation of RMD,s ... now houses close to 500,employees, including 120 members ...
Cached Biology Technology:Vasogen Announces First Quarter 2008 Results 2Vasogen Announces First Quarter 2008 Results 3Vasogen Announces First Quarter 2008 Results 4Vasogen Announces First Quarter 2008 Results 5Vasogen Announces First Quarter 2008 Results 6Vasogen Announces First Quarter 2008 Results 7Vasogen Announces First Quarter 2008 Results 8Vasogen Announces First Quarter 2008 Results 9Vasogen Announces First Quarter 2008 Results 10Vasogen Announces First Quarter 2008 Results 11Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3
(Date:7/22/2014)... has shown squirrels have adapted to New York City,s ... if not better, than their fellow squirrels in the ... Department of Environment & Agriculture, led the study that ... behaviour in urban environments and prevent unnecessary responses when ... on the footpath. , "As we rapidly increase ...
(Date:7/22/2014)... as a world-famous vacation spot with natural tourism resources, a ... The Korea Institute of Geoscience and Mineral Resources (KIGAM) indicated ... volcanic eruption was evident 5,000 years ago. That is the ... spewed out of a volcano 5,000 years ago in the ... the whole peninsula. , The research team led by Dr. ...
(Date:7/22/2014)... , July 22, 2014 NXT-ID, Inc., ... growing m-commerce market, announces its next generation smart wallet, ... consumer oriented television show that airs on the ... NewsWatch regularly features top technology products ... 31st on the History Channel (6:00-6:30am ET/PT) and ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2Jeju Island is a live volcano 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 3
... Thirty to fifty percent of the global conversion of nutrients ... of the National Academy of Science of the United States ... state that this conversion is not carried out by denitrifying ... Nitrogen compounds act as fertilizers and are the ecological basis ...
... with variant Creutzfeldt-Jakob (vCJD) prions may no longer be ... a transfusion. Pall Corporation (NYSE: PLL) announced today the ... Prion Reduction Filter System. It is the first and ... the causative agent of vCJD from red cells, the ...
... only three months after deciding to create an ... trial registry and results database using an independent ... trials can be accessed by anyone, anywhere, with ... give patients and healthcare providers ready access to ...
Cached Biology News:Anammox bacteria produce nitrogen gas in oceans' snackbar 2Anammox bacteria produce nitrogen gas in oceans' snackbar 3First technology to remove prions that cause vCJD from blood launched 2First technology to remove prions that cause vCJD from blood launched 3First technology to remove prions that cause vCJD from blood launched 4Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Biology Products: